I-Tirzepatide iyinoveli ekabili ye-GIP/GLP-1 receptor agonist ebonise isithembiso esihle ekwelapheni izifo ze-metabolic. Ngokulingisa izenzo zamahomoni amabili emvelo e-incretin, athuthukisa ukukhiqizwa kwe-insulin, acindezele amazinga eglucagon, futhi anciphise ukudla okudlayo—okusiza ngempumelelo ukulawula ushukela wegazi nokukhuthaza ukuncipha kwesisindo.
Ngokuya ngezinkomba ezigunyaziwe, i-tirzepatide njengamanje igunyazwe ukuphatha ushukela wegazi ezigulini ezinesifo sikashukela sohlobo 2 kanye nokulawulwa kwesisindo eside kubantu abanokukhuluphala ngokweqile noma abakhuluphele ngokweqile. Ukusebenza kahle komtholampilo kwayo kusekelwa kakhulu izifundo eziningi: uchungechunge lwesilingo se-SURPASS lubonise ukuthi i-tirzepatide inciphisa kakhulu amazinga e-HbA1c kuwo wonke imithamo ehlukahlukene futhi idlula ukwelashwa okukhona njenge-semaglutide. Ekulawulweni kwesisindo, izivivinyo ze-SURMOUNT zilethe imiphumela encomekayo—ezinye iziguli zabhekana nokuncishiswa kwesisindo somzimba cishe ngo-20% phakathi nonyaka, zabeka i-tirzepatide njengenye yemithi elwa nokukhuluphala kakhulu emakethe.
Ngaphandle kwesifo sikashukela nokukhuluphala, ukusetshenziswa okungenzeka kwe-tirzepatide kuyanda. Izivivinyo zomtholampilo eziqhubekayo zihlola ukusetshenziswa kwayo ekwelapheni izimo ezifana ne-non-alcohol steatohepatitis (NASH), isifo sezinso esingamahlalakhona, nokuhluleka kwenhliziyo. Ngokuphawulekayo, esivivinyweni se-SUMMIT sesigaba sesi-3, i-tirzepatide ibonise ukuncipha okukhulu kwezehlakalo ezihlobene nokwehluleka kwenhliziyo phakathi kweziguli ezinokwehluleka kwenhliziyo ezinengxenyana yokukhipha evikelekile (i-HFpEF) kanye nokukhuluphala, enikeza ithemba elisha lokusetshenziswa okubanzi kokwelapha.
Isikhathi sokuthumela: Jul-24-2025